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ABSTRACT
Interleukin-15 (IL-15) is a potent cytokine that increases CD8+ T and NK cell 
numbers and function in experimental models. However, obstacles remain in using 
IL-15 therapeutically, specifically its low potency and short in vivo half-life. To 
help overcome this, a new IL-15 superagonist complex comprised of an IL-15N72D 
mutation and IL-15RαSu/Fc fusion (IL-15SA, also known as ALT-803) was developed. 
IL-15SA exhibits a significantly longer serum half-life and increased in vivo activity 
against various tumors. Herein, we evaluated the effects of IL-15SA in recipients 
of allogeneic hematopoietic stem cell transplantation. Weekly administration of 
IL-15SA to transplant recipients significantly increased the number of CD8+ T cells 
(specifically CD44+ memory/activated phenotype) and NK cells. Intracellular IFN-γ 
and TNF-α secretion by CD8+ T cells increased in the IL-15SA-treated group. IL-15SA 
also upregulated NKG2D expression on CD8+ T cells. Moreover, IL-15SA enhanced 
proliferation and cytokine secretion of adoptively transferred CFSE-labeled T cells in 
syngeneic and allogeneic models by specifically stimulating the slowly proliferative 
and nonproliferative cells into actively proliferating cells. 
We then evaluated IL-15SA’s effects on anti-tumor activity against murine 
mastocytoma (P815) and murine B cell lymphoma (A20). IL-15SA enhanced graft-
versus-tumor (GVT) activity in these tumors following T cell infusion. Interestingly, 
IL-15 SA administration provided GVT activity against A20 lymphoma cells in the 
murine donor leukocyte infusion (DLI) model without increasing graft versus host 
disease. In conclusion, IL-15SA could be a highly potent T- cell lymphoid growth 
factor and novel immunotherapeutic agent to complement stem cell transplantation 
and adoptive immunotherapy.
INTRODUCTION 
IL-15 is a pleiotropic cytokine, which plays various 
roles in the innate and adaptive immune systems, including 
the development, activation, homing and survival of 
immune effector cells, especially NK, NK-T and CD8+ 
T cells [1]. IL-15, a member of the common gamma 
chain (γc) cytokine family, binds to a receptor complex 
that consists of IL-15Ra, IL-2Rβ and the γc chain [2, 3]. 
Furthermore, IL-15 functions as a key regulator in the 
development, homeostasis and activity of NK cells [4, 5]. 
IL-15 administration to normal mice or overexpression 
of IL-15 in a transgenic mouse model increases the 
number and percentage of NK cells in the spleen [6, 7], 
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the proliferation and survival of NK cells, as well as their 
cytolytic activity and cytokine secretion. Our laboratory 
and others have previously shown that IL-15 administration 
can increase the NK cell number and function in recipients 
of stem cell transplantation [8–11].
The primary limitations in clinical development of 
recombinant human IL-15 (rhIL-15) are low production 
yields in standard mammalian cell expression systems and 
a short serum half-life [12, 13]. Moreover, the formation 
of the IL-15:IL-15Rα complex, with both proteins co-
expressed in the same cell, can stimulate immune effector 
cells bearing the IL-2βγc receptor through a trans-
presentation mechanism. The studies have shown that IL-
15/IL-15Rα complex increases the affinity of the IL-15 to 
the IL-2Rβ approximately 150-fold, when compared with 
free IL-15 [14]. Various, types of complexes between IL-
15 and soluble IL-15Rα have been generated that exhibit 
an enhanced biological activity and increased anti-tumor 
responses in animal models [15–17]
A superagonist mutant of IL-15 (IL-15N72D), 
which has increased Rβγc binding ability (4-5 fold higher 
than native IL-15) has been identified for therapeutic 
usages [18]. 
Based on these findings, the strong interaction of 
IL-15N72D and soluble IL-15Rα was exploited to create 
a new IL-15 superagonist complex with the IL-15N72D 
bound to the IL-15RαSu/Fc. The soluble fusion protein, 
IL-15RαSu/Fc, was created by linking the human IL-
15RαSu domain with human IgG1 containing the Fc 
domain. Studies on IL-15:IL-15Rα complexes show 
an advantage of increased intracellular stability of IL-
15 [19, 20]. Co-expression of both the IL-15N72D and 
IL-15RαSu/Fc proteins resulted in a soluble and stable 
complex with significantly longer serum half-life and 
increased biological activity, compared to native IL-15 
[21], which was consistent with the results previously 
shown with other IL-15/IL-15Rα complexes [15–17, 22, 
23]. As indicated above, this IL-15N72D:IL-15RαSu/Fc 
complex (IL-15SA, or ALT-803) was found to be >10-
fold more active than free IL-15 in promoting in-vitro 
proliferation of IL-15-dependent cells [18]. 
IL-15 SA was previously shown to have potent anti-
tumor activity in syngeneic murine models of multiple 
myeloma [24]. Here we show the potent effects of IL-
15 SA on immune reconstitution and graft-versus-tumor 
(GVT)/ graft versus leukemia (GVL) activity in recipients 
of allogeneic hematopoietic stem cell transplantation 
(HSCT) in murine models.
RESULTS 
Effects of IL-15SA on immune cells following 
HSCT
We first evaluated the effects of IL-15SA in 
T-cell depleted murine BMT models. We used two 
different MHC-mismatched allotransplant models. We 
have extensively investigated enhancement of immune 
reconstitution in our previous studies by cytokines and 
growth factors [10, 25–28]. The early reconstitution 
requires minimum 2-3 weeks post-transplant. Therefore, 
we administered cytokines either between days 21 and 
day 28 or days 14-28. We aimed to cover the same 
period in this study with day 17 and 24 administration 
schedule.
Lethally irradiated BALB/c recipients were 
transplanted with T cell depleted (TCD) bone marrow 
(BM) cells from B6 mice. IL-15SA was administered via 
intraperitoneal (i.p.) injection in two doses on days 17 
and 24 after transplant. Animals were sacrificed on day 
28. All recipients had more than 90% engraftment in the 
spleens and BMs. There was no significant difference 
in engraftment and cellularity in the spleens and BMs 
between IL-15SA and control groups (data not shown). 
Administration of IL-15SA significantly increased the 
number of CD8+ T and NK cells, whereas there was no 
change in CD4+ T cell numbers (Figure 1A). IL-15SA 
mostly increased CD8+ memory T cell population 
(CD44high) (data not shown). We observed similar activity 
in B6CBACB6F1 transplant model (Figure 1B), in 
which the animals were treated with the same dose and 
schedule. IL-15SA also augmented intracellular IFN-γ 
secretion by CD8+ but not CD4+ T cells in this model 
(Figure 1C).
We then tested the effects of prolonged 
administration of IL-15SA on T cell reconstitution in 
an allogeneic transplant model. Again, recipients were 
treated with IL-15SA i.p. on days 28, 35 and 42 after 
MHC-mismatched HSCT (B6 ® B6D2F1). We found that 
IL-15SA administration increased the CD8+ memory/
effector T cell population, but did not show any activity 
on both CD4+ memory and naïve T cell populations. 
Interestingly, CD8+ naïve T cells also remained unaffected 
in both IL-15SA treated and untreated groups (Figure 
2A). We also evaluated other activation markers on the 
lymphocytes. Interestingly, we found a 10-fold increase in 
NKG2D expression on CD8+ T cells, suggesting that some 
CD8+ T cells turn into effector/cytotoxic lymphocytes 
with innate-like phenotype (Figure 2B) after exposure 
to IL-15SA. These effects of IL-15SA on immune cells 
after HSCT are similar to previously observed changes 
in preclinical studies [29]. We did not find a significant 
change of surface CD107a expression on both CD4+ or 
CD8+ T cells, which is a marker of degranulation of the 
cytolytic perforin/granzyme pathway against the tumors 
(data not shown).
We then did another experiment to test the duration 
of IL-15 SA effects in our models. B6D2F1 recipients 
were lethally irradiated and transplanted with TCD B6 
BM cells. The recipients were treated with IL-15 SA 
on days 35, 42 and day 49 and harvested on day 63 
after allogeneic HSCT. observed similar spleen and 
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CD4+T cell counts, but CD8+T cells T cells significantly 
increased two weeks after the last dose of IL-15 SA 
(Figure 2C). We concluded that the effects of IL-15 SA 
on immune reconstitution last at least two weeks after the 
administration. 
We further examined the effects of IL-15SA 
on allogeneic proliferating cells in murine models. 
CFSE (carboxyfluorescein succinimidyl ester) labeled 
splenocytes from B6 mice were transferred into lethally 
irradiated B6D2F1 recipient mice. IL-15SA was given 
on the same day after splenocytes infusion. All animals 
were sacrificed three days after splenocyte infusion. IL-
15SA treatment specifically promoted proliferation of 
slow-proliferating CD8+ T cells in conjunction with robust 
IFN-γ and TNF-α secretion, in allogeneic recipients of 
CFSE labeled-T-cell infusion. However, there was no 
effect of IL-15SA on CD4+ T cell proliferation (Figure 
3A). Interestingly, we have not seen a significant 
increase in TNF-a secretion by CD8+ T cells following 
IL-15 administration in previous experiments [28], 
suggesting that IL-15SA is more potent than native IL-
15 for inducing cytokine secretion in CD8+ T cells in 
vivo. We then evaluated IL-15SA activity in syngeneic 
recipients of CFSE labeled T-cell infusion. Again, we 
found that IL-15SA increased proliferation and IFN-γ 
secretion in adoptively transferred CD8+ T cells, but it 
did not increase their TNF-a secretion (Figure 3B). These 
results further suggest that additional stimulatory signals, 
such as TCR-MHC engagement in the allogeneic rather 
than the syngeneic adoptive T cell transfer setting, are 
potentially necessary to induce TNF-α secretion by IL-
15SA stimulation.
Antitumor activity of IL-15SA in murine tumor 
models
Next, we tested the anti-tumor activity of IL-15SA in 
two different tumor models; murine mastocytoma (P815) 
and murine B cell lymphoma (A20). First, we evaluated 
anti-tumor activity of IL-15SA in the P815 model, without 
T cell administration. We could not detect any significant 
graft-versus-tumor (GVT) activity in recipients of P815 
in parent-F1 model when IL-15SA was administered 
without the T cell infusion (data not shown). When we 
infused a small amount of T cells into the B6®B6D2F1 
model, we found that IL-15SA administration significantly 
enhanced anti-tumor activity against P815 tumor cells 
with two different T cell doses; 5 × 104 and 1 × 105 cells, 
respectively (Figure 4A and 4B). We did not observe any 
significant signs of GVHD in these experiments. Only 
two animals had a GVHD score of 1 because of minimal 
weight loss, which might be related tumor growth (in 
Figure 4A and no sign of GVHD in 4B). All animals 
died from tumor development with hind leg paralysis or 
presence of tumor metastasis in the autopsy. Therefore, 
IL-15SA administered with T cell infusion in the P815 
model, provided a limited benefit to the tumor-bearing 
mice, compared to the control group.
In the A20 murine lymphoma model, we evaluated 
anti-lymphoma activity against A20 cells in recipients of 
allogeneic HSCT, with or without T cell infusion. A20 
cells were kindly provided by Dr. Marcel van den Brink’s 
laboratory (Memorial Sloan–Kettering Cancer Center, New 
York, NY), expressing triple gene construct with luciferase 
activity that allowed us to detect tumor growth with 
Figure 1: IL-15SA administration increases CD8+ T and NK cell numbers after transplantation. (A) Lethally irradiated 
(11Gy) Balb/c recipients were transplanted with 5 × 106 T-cell depleted (TCD) bone marrow (BM) cells from B6 mice. IL-15SA was 
administered via IP injection at 1 μg per mouse in two doses on days +17 and +24. Mice were sacrificed at day 28 after transplant, and 
spleens, thymi and BM were harvested. Single cell suspensions were prepared and stained with anti-H2Kd, -CD3, -CD4, -CD8, -Gr-1, 
-NK1.1, and -B220 antibodies, and analyzed with a flow cytometer. Each group contains 5 mice. Splenic numbers of CD4+ T, CD8+ T, 
and NK cells, are shown. *P < 0.05. Figure 1B and 1C. Lethally irradiated (12Gy) CB6F1 recipients were transplanted with 5 x 106 T-cell 
depleted (TCD) bone marrow (BM) cells from B6CBA mice. IL-15 super agonist was administered via IP injection at 1 μg per mouse in 
two doses on days 17 and 24. Mice were sacrificed at day 28 after transplant, and spleens, thymi and BM were harvested. After preparation 
of single cell suspensions, cells were stained with anti-H2Kd, -CD4, -CD8 (B). Some splenocytes are also incubated as described for 
intracellular staining, then harvested and stained with anti-H2Kd, -CD4, -CD8 and IFN-γ antibodies and analyzed with a flow cytometer 
(C). Each group contains 5 mice. *P < 0.05
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bioluminescence imaging (BLI). First, we developed an 
A20 murine tumor model and found that infusion of 1 × 105 
donor T cells provided a significant anti-tumor activity 
and survival benefit in the B6CBAF1 → CB6F1 (MHC-
mismatched) model. Thus, we lethally irradiated CB6F1 
mice and transplanted B6CBAF1 BM along with 1 × 105 T 
cells. All animals received A20 tumor cells on the same day 
as the BM transplant. We found that all animals survived in 
the IL-15SA-treated group, which is statistically significant 
compared to the control group (Figure 4C). 
We then explored anti-lymphoma/leukemia activity 
of IL-15SA in allogeneic HSCT recipients, without any T 
cell infusion in the A20 model. Same dose and route of IL-
15SA were used as previously described. Tumor growth 
was determined by intensity of photon measurements 
using IVIS bioluminescence system (Figure 5A, 5B). 
Although we observed that two administrations of IL-
15SA could provide a delay of A20 cell growth in vivo, 
the delayed tumor growth by IL-15SA administration did 
not result in survival difference between the IL-15SA and 
Figure 2: IL-15SA administration increases CD8+ CD44+ and CD8+NKG2D+ effector/memory T cells. Lethally irradiated 
(12Gy) B6D2F1 recipients were transplanted with 5 × 106 T-cell depleted (TCD) bone marrow (BM) cells from B6 mice. IL-15SA was 
administered via IP injection at 2.5 μg per mouse on days 28, 35 and 42. Mice were sacrificed at day 49 after transplant, and spleens were 
harvested. Single cell suspensions were prepared and stained with anti-H2Kd, -CD3, -CD4, -CD8, -CD44 and -NKG2D antibodies. Cells 
were acquired and analyzed with a flow cytometer (A and B). IL-15SA was administered via IP injection at 2.5 μg per mouse on days 35, 
42 and 49. Mice were sacrificed at day 63 after transplant, and spleens were harvested. Single cell suspensions were prepared and stained 
with anti-H2Kd, -CD3, -CD4, -CD8, and -CD44 (C).
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the control group (Figure 5C). Interestingly, IL-15SA is 
still successful in generating anti-tumor activity against 
A20 lymphoma cells without a T cell infusion.
Taken together, the results of these experiments 
indicate that IL-15SA significantly increases the anti-
lymphoma /leukemia activity in murine HSCT by 
effectively promoting the effector/memory CD8+ T and 
NK cell expansion and potently enhancing their effector 
functions. 
IL-15SA enhances anti-tumor activity with 
donor leukocyte infusion (DLI)
DLI has been developed as a strategy for 
management of relapse by increasing graft-versus-tumor 
effects after allogeneic HSCT [30]. DLI is used in nearly 
all malignant hematological diseases for which allogeneic 
HSCT is performed. However, the response to DLI varies 
with respect to the methods of cell collection, timing, 
Figure 3: IL-15SA administration increases cytokine secretion and proliferation of CD8+ T cells in recipients of CFSE 
labeled T cells. Lethally irradiated (1300 cGy) either B6D2F1 (A) or B6(Ly5.1) mice (B) were transplanted with CFSE labeled B6 
splenocytes (30 × 106) at day 0 and given either IL-15SA or a vehicle control (Day 0 post infusion). Mice were sacrificed on day 3 after 
CFSE labeled leukocyte infusion and splenocytes were stained with anti-CD4, -CD8, CD45.1 and -H2Kd antibodies. Cells then were 
analyzed by flow cytometry. Intracellular staining with anti-IFN-γ and anti-TNF-α antibodies after PMA and ionomycin stimulation was 
performed. Red line indicates boundary of isotypic control and arrows indicate increase in IFN-γ secretion in the slow proliferating CD8+ 
T cells. 
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cell dose infused, and even cell sub-type used (reviewed 
in [31]). To enhance the efficacy of DLI infusion would 
improve the outcome the patients who relapse after 
allogeneic HSCT. Therefore, we studied whether IL-
15SA can be used to enhance the efficacy of DLI in animal 
models. To achieve this, we first developed a DLI model 
with recipients of allogeneic HSCT. Lethally irradiated 
CB6F1 recipients were transplanted with T-cell-depleted 
B6 BM cells. A20 murine lymphoma cells were infused 
at the day of transplant. Purified T cells were infused after 
tumor growth in recipients of allo HSCT. We found that a 
moderate dose of T cell infusion (2.5 × 105 cells) provides 
GVL activity after tumor development in recipients of 
allo-HSCT (data not shown). The IL-15SA-treated group 
exhibited a better survival and less weight loss after 
transplant compared to the untreated group (Figure 6A and 
Figure 6B). We also monitored tumor growth in all animals 
with BLI. We found that IL-15SA administration resulted 
in significantly decreased photon intensity by BLI, which 
suggests IL-15SA was able to inhibit tumor growth (Figure 
6C and 6D). 20% of recipients in the IL-15 SA group had 
score of 1, related to weight loss and mobility. No animals 
died from GVHD in the IL-15SA group. 30% animals had 
a low GVHD score between 1-2 in the control-DLI group. 
Only one animal died from GVHD in the control group. 
All other animals died from progression of leukemia/
lymphoma (they have either a significant tumor growth or 
hind leg paralysis, which is a sign of tumor growth). We 
concluded that we did not observe an increase in GVHD 
score and weight loss in IL-15SA-treated group compared 
to the control group (Figure 6B) suggesting that IL-15SA 
did not promote GVHD in this murine HSCT model after 
a low dose T-cell infusion. Thus, IL-15SA administration 
after allogeneic HSCT enhances GVL/lymphoma activity 
without aggravating GVHD in the low-dose DLI murine 
models.  
DISCUSSION
We have previously shown that IL-15 enhances 
anti-tumor activity in recipients of allogeneic and 
haploidentical HSCT [10, 28]. IL-15 half-life is roughly 
1 hour after administration and must be administered daily 
for treatment [15]. The long-term effects of recombinant 
human IL-15 (rhIL-15) have been studied in non-human 
primates, demonstrating that daily administration of IL-15 
for 8-14 days resulted in lymphocytosis and leukocytosis, 
and white blood cell count returned to normal after 
discontinuation of IL-15 on day 28 in these studies [32]. 
Immunological parameters also returned to baseline on 
day 28 in the same studies. Due to the limitations with 
the short half-life and daily administration of IL-15, 
alternative dosing strategies of IL-15 require further 
assessment in the therapeutic setting. 
Recently, Conlaon et al. reported that recombinant 
human interleukin-15 administration resulted in NK 
and CD8+ T cells redistribution, proliferation, activation 
of NK and CD8+ T cells and enhanced inflammatory 
cytokine production after daily bolus infusion [33]. 
Authors also mentioned that alternative dosing strategies 
have been studied to decrease the toxicity of cytokine. 
IL-15 SA (ALT-803) with a better safety profile and a 
Figure 4: IL-15SA administration increases GVT activity after transplant. (A and B) Lethally irradiated (13Gy) B6D2F1 
recipients were transplanted with 5 × 106 T-cell depleted (TCD) bone marrow (BM) cells from B6 mice. All recipients also received 1 × 
104 P815 cells on the day of transplantation along with 5 × 104 (4A) or 1 × 105 (4B) purified B6 T-cells. IL-15SA was administered via IP 
injection at 2.5 μg per mouse in two doses on days 7 and 14. Kaplan Mayer curves for this transplant modality are depicted as follows; 
vehicle control (black line) and IL-15 super agonist (red line). * = p < 0.05, and each group had 15 mice. (C) Lethally irradiated (13Gy) 
CB6F1 recipients were transplanted with 5 × 106 T-cell depleted (TCD) bone marrow (BM) cells from B6 mice. All recipients also received 
5 × 105 A20 cells on the day of transplantation along with 1 × 105 purified B6 T-cells. IL-15SA was administered via IP injection at 2.5 μg 
per mouse in two doses on days 7 and 14. Kaplan Mayer curves for this transplant modality are depicted as follows; vehicle control (black 
line) and IL-15 super agonist (red line). *=p < 0.05, and each group had 10 mice.
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longer half-life will potentially provide an advantage in 
clinical use. 
We have shown in this study that a new IL-
15 superagonist complex, IL-15SA, is a potent 
immunotherapeutic agent for stimulating NK and CD8+ T 
cells in recipients of allogeneic HSCT in murine models. 
IL-15SA promoted the expansion of CD8+ memory T 
cells and NK cells but not CD4+ T cells. IL-15SA also 
significantly increased the levels of NKG2D expression 
on CD8+ T cells. NKG2D, an activating receptor of innate 
immune cells, is mainly expressed on the surface of NK 
cells, γδ T cells, and activated CD8+ T cells. The NKG2D 
receptor plays a pivotal role in both innate and adaptive 
immunity against tumorigenesis and tumor surveillance 
[34, 35]. In the previous studies, IL-15SA induced 
memory CD8+ T cells to proliferate, upregulate receptors 
involved in innate immunity, secrete IFN-γ and acquire the 
ability to kill malignant cells in the absence of antigenic 
stimulation in murine models of multiple myeloma [24]
The studies described in this paper demonstrate for 
the first time that IL-15SA may have similar effects on the 
immune cells in the HSCT setting. Thus, it is conceivable 
that CD8+ T cells with high NKG2D expression (i.e., 
NKT cells) are induced by IL-15SA, and contributed to 
potent anti-A20 tumor activity in HSCT. This is consistent 
with the results from a recent report that showed NKG2D 
expression on CD8+ T cells is related to mediating GVHD 
and GVT by promoting the survival and cytotoxic function 
of CD8+ T cells [36]. NKG2D blockade was shown to 
attenuate GVHD, while allowing CD8+ T cells to regain 
anti-tumor activity. Besides functioning as an activating 
receptor for cell-mediated cytotoxicity of T-NK cells 
against tumors, NKG2D has also been suggested to act 
as a receptor to recruit T-NK cells to the tumor sites in 
which tumor cells overexpress stress-inducible NKG2D 
ligands [37]. 
In this study, we continue to observe the 
phenomenon of the IL-15SA not significantly promoting 
CD4+ T cell proliferation and activation. We have shown 
that IL-15 SA increased CD8+ T cell proliferation 
and IFN-g and TNF-a secretion from CD8+ T cells in 
recipients of allogeneic CFSE-labeled splenocyte infusion. 
Increased TNF-a secretion in allogeneic model might be 
related toan increase in T cells that may not be detectable 
in syngeneic model. These data may suggest that IL-15 
SA may aggravate GVHD in allogeneic , though we have 
Figure 5: IL-15SA delays A20 lymphoma cells growth in recipients of HSCT. Lethally irradiated (12Gy) CB6F1 recipients 
were transplanted with 5 × 106 T-cell depleted (TCD) bone marrow (BM) cells from B6 mice. All recipients also received 5 × 105 A20 cells 
on the day of transplantation along without T cell infusion. IL-15SA was administered via IP injection at 2.5 µg per mouse in two doses 
on days +7, and +14. In vivo luminescent imaging of experiment is shown in (A) Mice were injected with luciferin at 3.75mg per mouse, 
allowed to incubate for 8 mins, and then imaged for 3 mins. Control group on the left, IL-15SA on the right. Photon intensity is calculated 
and shown in (B) *= p < 0.05, and each group had 10 mice.
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not seen this in our low dose T cell models Interestingly, 
IL-15SA increases IFN-g and TNF-a secretion from slow 
proliferative CD8 (+) T cells that may resemble the more 
homeostatic expansion of T cell in the lymphopenic 
environment [10, 25, 28] 
We have previously shown that IL-15 administration 
after allogeneic HSCT may enhance the occurrence of 
GVHD in T cell-repleted models, but it does not have 
effect on GVHD after TCD-BMT [10]. Interestingly, IL-
15 did not increase GVHD in recipients of a very low 
dose T cell infusion [28]. Using the same model in this 
study, we also found that IL-15SA did not increase the 
occurrence of GVHD and resulted in improved survival 
of haploidentical HSCT recipients of tumor bearing mice. 
Herein, we demonstrated that IL-15SA increased NK cell 
numbers in recipients of haploidentical HSCT. IL-15SA 
has also been shown to potently activate the cytotoxicity 
of NK cells [38]. NK cell alloreactivity in recipients 
of mismatched HSCT may suppress development of 
GVHD by decreasing host-derived antigen presenting 
cells [39]. Thus, it is conceivable that the increase of NK 
cell numbers and the enhancement of their cytotoxicity 
by IL-15SA administration in haploidentical HSCT not 
only contribute to the GVT but also decrease host-derived 
antigen presenting cells. The decrease in host-derived 
antigen presenting cells reduces the activation of host-
specific CD8+ effector T cells which are responsible for 
GVHD. However, NK cell-associated GVT activity was 
Figure 6: IL-15SA increases anti-tumor activity after DLI infusion in murine leukemia/lymphoma model. Lethally 
irradiated (12Gy) CB6F1 recipients were transplanted with 5 × 106 T-cell depleted (TCD) bone marrow (BM) cells from B6 mice. All 
recipients also received 5 × 105 A20-TGL (H2Kd) lymphoma cells with triple fusion gene carrying luciferase activity on the day of 
transplantation. The recipients of transplant received none or 2.5 × 105 B6 T-cells isolated via CD5+ magnetic separation on day 14 after 
transplant. Animals received either intraperitoneal (IP) injections of IL-15 SA (1ug per mouse) or control on days 17 and 24 after transplant. 
Survival and weight curves of the groups are depicted as (A and B) (N = 10–20). Serial bioluminescence images are obtained by IVIS 
machine in varying time points as show. A20-TGL cells express Luciferase protein allowing in vivo bioluminescent imaging; mice were 
injected with 3.75mg Luciferin, incubated for 5 mins, and imaged for 3 mins. Serial bioluminescence images are obtained by IVIS machine 
in varying time points as show (C) representative of independent of two experiments). Control group on the left, IL-15 SA group on the 
right. Total flux (photons/sec) was measured for each mouse at each time point and plotted as a curve (D). 
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apparently not strong enough to overcome the A20 tumor 
growth and improve the overall survival of the A20 
lymphoma bearing recipient without T cell infusion pre- 
or post-transplant. Only a low dose of T cell infusion was 
shown to be required to provide survival advantage in the 
IL-15SA treatment group. This is likely the result of IL-
15SA’s unique capabilities of promoting the expansion 
of CD8+ memory T cells and enhancing their effector 
functions. 
DLI has been developed as a strategy for relapse-
management by increasing GVT effects after allogeneic 
HSCT [30]. DLI is used to treat most malignant 
hematologic diseases in recipients with relapsed disease 
after HSCT. The general response rate is less than 30% 
in patients with acute leukemia and is not durable [31]. 
Collins et al. has found the response rate to DLI to be 
less than 20% in acute leukemia patients [40]. In recent 
years, new methods have been developed to enhance 
the efficacy of DLI for the treatment of relapsed or 
persistent hematological malignancies after allogeneic 
HSCT [41]. Enhancing donor leukocyte activity with 
various cytokines has been explored. Interleukin-2 
treatment after DLI in patients with relapsed leukemia 
after allo HSCT did not provide beneficial outcome, and 
increased the occurrence of GVHD [42]. Interleukin-15 
has never been used following DLI in humans or murine 
transplant models.
The activity of DLI in murine models is affected 
by donor/host MHC Ag disparity, DLI dose, and tumor 
type. We developed the DLI model against the A20 murine 
lymphoma model system. In this model, we could detect a 
significant anti-tumor activity of DLI with a combination 
of IL-15 SA. We think that a major differences in our 
models and published data are T cell dose and the timing 
of tumor infusion. 2–5 × 107 splenocytes were infused in 
the previous DLI studies in murine models [43–46]. T cell 
dose in those studies was approximately 1–2 log higher 
than the dose that was used in our studies (2.5 × 105). As 
a result of that, the occurrence of GVHD diminished in 
this study. The timing of the tumor/leukemia cell infusion 
is also different in our study. We tried to mimic the 
clinical scenario for DLI infusion. The therapeutic DLI 
infusion is given after leukemia recurrence post-transplant 
in the patients with allogeneic HSCT. We aimed to test 
the efficacy of DLI after tumor development. Therefore, 
tumor cells were infused on the day of the transplant and 
the most of the recipients were detectable tumor by BLI at 
day 14 after HSCT. When we tested the timing of DLI, we 
observed that infusion at day 21 might be late to overcome 
the tumor development with a low dose T cell infusion 
(data not shown). 
Our studies focused on exploring the activity of 
purified T cell-containing DLI and results revealed that 
IL-15SA administration significantly enhanced the activity 
of DLI in murine lymphoma model. Safety and feasibility 
of DLI and an IL-15SA combination would be further 
investigated in the future clinical studies. We have recently 
begun studies in non-transplant lymphoma models, and 
preliminary data reveals that IL-15SA can increase anti-
lymphoma activity of autologous T cell infusion in normal 
mice after lymphodepletion, suggesting that IL-15SA may 
play a role in the lymphoma/leukemia therapy.
Herein, we have demonstrated that once a week 
administration of IL-15SA could provide sustained 
immunological activity and anti-tumor activity in 
murine tumor models, murine mastocytoma and murine 
B cell lymphoma. Substantial anti-tumor activity of IL-
15SA has also been previously reported against multiple 
myeloma in syngeneic models [24]. This is likely due to 
the longer serum half-life of IL-15SA and its favorable 
pharmacokinetic profile compared to rhIL-15 [21]. 
The results of these studies support the weekly dosing 
regimen currently in various clinical trials for solid and 
hematological malignancies (Personal communication- Dr 
Wong, Altor Bioscience). 
In summary, IL-15SA is a potent lymphoid growth 
factor and could be used as a powerful therapeutic for 
boosting the immune function in recipients of stem 
cell transplantation and adoptive T cell therapy without 
exacerbating GVHD. An evaluation of its clinical utility 
for stem cell transplantation and adoptive cellular 
therapies is warranted.  
MATERIALS AND METHODS
Mice and bone marrow transplant (BMT)
Female C57BL/6 (B6, H-2Kb), Balb/c (H-2Kd), 
B6CBAF1 (H-2Kb/k), CB6F1 (H-2Kb/d) and B6D2F1 
(H2Kb/d) mice were obtained from the Jackson Laboratory 
(Bar Harbor, ME). Mice used in BMT experiments were 
between 10–-12 weeks of age. BMT protocols were 
approved by the Institutional Animal Care and Use 
Committee (IACUC) at Thomas Jefferson University.
Bone marrow (BM) cells were removed aseptically 
from femurs and tibias and T cells depleted (TCD) by 
incubation with anti-Thy 1.2 antibody for 30 min at 
4°C, followed by incubation with Low-TOX-M rabbit 
complement (Cedarlane Laboratories, Hornby, Ontario, 
Canada) for 40 minutes at 37°C, or alternatively via anti-
CD5 magnetic bead depletion (Miltenyi, Auburn, CA). 
Typical levels of contaminating T cells after complement 
depletion ranged from 0.2 to 0.5 percent of all bone 
marrow leukocytes.
Splenic T cells were obtained by positive selection 
with anti-CD5 antibodies conjugated to magnetic beads 
(Miltenyi, Auburn, CA). Cells (5x106 BM cells with or 
without splenic T cells) were resuspended in Dulbecco 
Modified Eagle’s Medium (DMEM) and transplanted by tail 
vein infusion (0.25 ml total volume) into lethally irradiated 
recipients on day 0. On day 0 prior to transplantation, 
recipients received 11 to 13 Gy total body irradiation (strain 
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dependent) from a 137Cs source as a split dose with a 3 hour 
interval between doses to reduce gastrointestinal toxicity. 
Mice were housed in sterilized micro-isolator cages and 
received normal chow and autoclaved hyper-chlorinated 
drinking water (pH 3.0).
Cell lines, antibodies, and cytokines
P-815 (H-2d) cell line was obtained from ATCC 
(Manassas, VA). A20 (H-2d) murine lymphoma cell line, 
retrovirally transduced to express a triple fusion protein 
consisting of Herpes simplex virus thymidine kinase, 
enhanced green fluorescent protein (eGFP) and firefly 
luciferase (TGL), was kindly provided by Dr. Marcel van 
den Brink (Memorial Sloan Kettering Cancer Center, New 
York, NY). Cells were cultured in RPMI with 10% FBS in 
atmosphere containing 5% CO2.
Anti–murine CD16/CD32 FcR block (2.4G2) and all 
of the following fluorochrome-labeled antibodies against 
murine antigens were obtained from BD Pharmingen (San 
Diego, CA): H2Kd (SF1-1.1), CD3 (500A2), CD4 (RM4-
5), CD8 (53-6.7), CD25 (PC61), CD44 (IM7), CD45R/
B220 (RA3-6B2), CD62L (MEL-14), NK1.1 (PK136), 
TNF-α (MP6-XT22), IFN-γ (XMG1.2), NK2GD, isotype 
controls; rat IgG2a-κ, rat IgG1-κ hamster, and IgG1-κ. 
Cytokine complex IL-15SA (ALT-803) was 
kindly provided by Altor BioScience Corporation, 
Miramar, Florida. IL-15SA (ALT-803) was administered 
intraperitoneally, weekly at 1-2.5 µg/day. 
Flow cytometry
Single cell suspension of 106 cells/25 μL was incubated 
at 4°C with CD16/CD32 FcR block. Subsequently, cells were 
incubated at 4°C with antibodies in a total volume of 50 μl. 
The stained cells were analyzed on a FACS Calibur flow 
cytometer (Becton Dickinson, San Jose, CA) with CellQuest 
software or LSRII cytometer (Becton Dickinson, San Jose, 
CA) with FlowJo software (Treestar, San Carlos, CA).
Assessment of graft-versus-host-disease
The severity of GVHD was assessed with a 
clinical GVHD scoring system as previously described 
[47]. Briefly, ear-punched animals in coded cages were 
individually scored every week using 5 clinical parameters 
based on a scale from 0 to 2: weight loss, posture, mobility, 
fur, and skin. A clinical GVHD index was generated by 
summation of the 5 criteria scores (0–10). Survival was 
monitored daily. Animals with scores of at least 5 were 
considered moribund and were sacrificed.
PMA-ionomycin stimulation and intracellular 
staining
Splenocytes were incubated with PMA (20 ng/mL) 
and ionomycin (1 µM) for 5 hours. Brefeldin A was added 
at a concentration of 10 µg/mL two hours following the 
addition of PMA and ionomycin. Cells were first stained with 
surface antibodies and then fixed and permeabilized with the 
BD Cytofix/Cytoperm Kit (BD Biosciences, San Diego, CA) 
and subsequently stained with intracellular antibodies. 
CFSE labeling
Cells were labeled with carboxyfluorescein 
succinimidyl ester (CFSE) as previously described [48]. 
Briefly, splenocytes were incubated with CFSE at a final 
concentration of 2.5 µM in PBS at 37°C for 20 minutes. 
Cells were then washed three times with PBS before 
intravenous injection. 
Statistics
All values shown in graphs represent the mean ± 
SEM. Survival data were analyzed using the Mantel-
Cox log-rank test. For all other analysis, nonparametric 
unpaired Mann-Whitney-U test was used.
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